Pluri Inc.
Close on Oct 19, 2026
- Market cap
- $9.08M
- P/E (TTM)
- –
- Dividend yield
- –
About Pluri
Biological Products, (No Diagnostic Substances), SIC 2836
Pluri Inc. is a biotechnology company that develops cell-based products, therapeutics, and related technologies using a proprietary three-dimensional cell expansion platform. The company's automated platform expands human, animal, and plant cells within a synthetic scaffold to support scalable cell manufacturing. Its activities encompass cell therapy and immunotherapy programs, contract development and manufacturing organization services, regenerative aesthetics and longevity initiatives, and food technology and bio-farming applications. Product candidates include placenta-derived cell therapies such as PLX-PAD and PLX-R18, as well as an allogeneic immunotherapy platform using placental mucosal-associated invariant T cells for solid tumors.
The company operates an in-house, industrial-scale cell manufacturing facility functioning under Good Manufacturing Practice standards on a self-declared basis. Pluri maintains clinical development activities and regulatory engagements across the United States, Europe, and Israel, alongside operations supported by subsidiaries in Israel and Germany. Its principal executive offices are located in Haifa, Israel.
Summary of the business section of Pluri's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pluri Inc.
- Founded
- 2001
- Headquarters
- Haifa, Israel
- Address
- Matam Advanced Technology Park, Building No. 5
- Phone
- 972-74-710-7171
- Website
- pluri-biotech.com
- Employees
- 92, Jun 30, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Nevada
- Fiscal year ends
- June 30
- Auditor
- Kesselman & Kesselman, Haifa, Israel
Stock & identifiers
- Ticker
- PLUR
- Exchange
- Nasdaq
- IPO date
- Mar 18, 2004
- Shares outstanding
- 12M, Sep 9, 2026
- Public float
- $15.19M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-8 reverse, May 9, 2024; 1-for-8 reverse, Apr 1, 2024; 1-for-10 reverse, Sep 12, 2019; 1-for-10 reverse, Jul 25, 2019; 1-for-200 reverse, Nov 26, 2007
- SEC CIK
- 1158780
- CUSIP
- 72942G203
- ISIN
- US72942G2030
- LEI
- 529900OZKMF7JGZMYM81
- EIN
- 98-0351734
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yaky Yanay | Chief Executive Officer, Director | 498,594 |
| Liat Zalts | Chief Financial Officer | 92,767 |
| Doron Shorrer | Director | 45,197 |
| Alexandre Weinstein Manieu | Director | 3,826,886 |
| Eitan Ajchenbaum | Director | 12,353 |
| Zami Aberman | Director | 155,684 |
| Rami Avraham Levi | Director | 18,967 |
| Maital Shemesh-Rasmussen | Director | 19,144 |
| Pinhas Doron Birger | Director | 19,178 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.50M | $577.09K | $326.88K | $-489 | – |
| FY2024 | $741.48K | $306.68K | $492.37K | $-406 | – |
| FY2023 | $2.63M | -$238.00K | $375.24K | $-344 | – |
| FY2022 Mr. Yaky Yanay | $1.30M | -$1.77M | $608.21K | $-2184 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of June 30, 2026, we employed a total of 92 full-time employees and 21 part-time employees, of whom 73 full-time employees and 14 part-time”
Corporate history
Events identified from SEC filings